Drugs / EphA2-targeted CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06972576 | May 2025 → Apr 2026 overdue | non-small cell lung carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EphA2-targeted CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06972576 ↗ |
| Modality | Cell therapy | “Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting EphA2” NCT06972576 ↗ |
| Target | EPHA2 | “Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting EphA2” NCT06972576 ↗ |